Lord Darzi addresses the 2024 Deutsche Bank Global Innovation Summit

In conversation with Professor Lord Ara Darzi

Our fireside chat with Lord Darzi covered national health system challenges, anti-microbial resistance and the importance of leveraging new technology

Facebook LinkedIn

Our Global Innovation Summit for 2024 was opened by Claudio de Sanctis, Head of the Private Bank and Member of the Management Board of Deutsche Bank, interviewing Professor Lord Ara Darzi, Paul Hamlyn Chair of Surgery at Imperial College London, the Royal Marsden Hospital and the Institute of Cancer Research, and our host for today’s event.

 

Darzi is a prominent figure in U.K. healthcare innovation and policy, with over 30 years of experience in the National Health Service (NHS) and a distinguished career in surgery and academia. He recently conducted a review of the NHS in England at the request of the U.K. government and de Sanctis took the opportunity to question him on this, on the threat of anti-microbial resistance (AMR) and on the role of academia in supporting European competitiveness – among many other topics.

 

Insights from Lord Darzi on today's top healthcare trends

 

The Darzi Review highlighted several critical issues with the NHS, including long waiting times for children and adolescents, poor access to acute services, and the overall decline in public health prior to the COVID-19 pandemic. At the Global Innovation Summit, he emphasized the need for data-driven approaches to address these challenges and for significant capital investment to improve healthcare infrastructure.

 

Climate change was also discussed, with Darzi commenting on its growing negative effect on health issues around the world, including mental health problems among adolescents as well as the increased spread of infectious diseases. At the same time, he pointed out, the healthcare sector has a substantial carbon footprint, with the pharmaceutical industry contributing significantly to global emissions.

 

In discussing the future of healthcare, Darzi highlighted the transformative potential of emerging technologies such as mRNA vaccines, artificial intelligence (AI), and data analytics. He noted that these technologies could revolutionize disease prevention, early detection, and treatment. However, he also emphasized the need for responsible regulation and public engagement to ensure the successful adoption and diffusion of these innovations.

Professor Lord Ara Darzi shows Claudio de Sanctis the Da Vinci Surgical System
  • Professor Lord Ara Darzi shows Claudio de Sanctis the Da Vinci Surgical System he used to perform the first surgery of its kind in the U.K., 24 years ago

Key takeaways from this session

  1. In public healthcare systems, data-driven decision making is essential: Darzi underscored the importance of using data to inform healthcare policies and practices, particularly in addressing systemic issues within the NHS.
  2. Significant capital investment in the NHS is crucial: Major improvements to healthcare infrastructure is necessary to improve service delivery and patient outcomes.
  3. The healthcare sector must adopt more sustainable practices: The healthcare sector must slash its carbon footprint while also addressing the health impacts of climate change.
  4. Emerging technologies have transformative potential: Innovations such as mRNA vaccines and AI have the potential to transform healthcare but require responsible regulation and public engagement.

In Europe, Middle East and Africa as well as in Asia Pacific this material is considered marketing material, but this is not the case in the U.S.

The value of an investment can fall as well as rise and you might not get back the amount originally invested at any point in time. Your capital may be at risk.

No assurance can be given that any forecast or target can be achieved. Forecasts are based on assumptions, estimates, opinions and hypothetical models which may prove to be incorrect. Past performance is not indicative of future returns. Performance refers to a nominal value based on price gains/losses and does not take into account inflation. Inflation will have a negative impact on the purchasing power of this nominal monetary value. Depending on the current level of inflation, this may lead to a real loss in value, even if the nominal performance of the investment is positive.

This web page is not an offer to buy a security or enter into any transaction. The products, services, information and/or materials contained within these web pages may not be available for residents of certain jurisdictions. Please consider the sales restrictions relating to the products or services in question for further information. Deutsche Bank does not give tax or legal advice; prospective investors should seek advice from their own tax advisers and/or lawyers before entering into any investment.

Change of name: As part of Deutsche Bank’s Private Bank, the former International Private Bank also adopted this title on July 20, 2023.